Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Department of Biomedical Sciences & Medicine, Oncology Division, University of Algarve, 8005-139 Faro, Portugal.
Future Oncol. 2018 Mar;14(6):567-575. doi: 10.2217/fon-2017-0486. Epub 2018 Feb 8.
The global burden of lung cancer has been increasing over the past years, and is still a major threat to public health worldwide, leading to disabilities and premature mortality. Despite multifactorial cause, smoking remains as the major etiological factor, followed by occupational exposure to carcinogens, genetic predisposition and other concomitant diseases. In order to reduce the individual and social burden due to the direct and indirect costs related to the lung cancer treatment, accurate methods of screening are needed. Among those, x-ray with cytological analysis of sputum was first proposed. Nowadays, more sensitive methods such as low-dose computed tomography are being used to improve the early detection. In the future, molecular biomarkers may complement low-dose computed tomography and improve the robustness of early lung cancer detection.
在过去的几年中,全球肺癌负担一直在增加,仍然是全世界公共卫生的主要威胁,导致残疾和过早死亡。尽管病因复杂,但吸烟仍然是主要的病因因素,其次是职业接触致癌物、遗传易感性和其他伴随疾病。为了降低与肺癌治疗相关的直接和间接成本给个人和社会带来的负担,需要有准确的筛查方法。在这些方法中,首先提出了 X 射线加痰细胞学分析。如今,更敏感的方法,如低剂量计算机断层扫描,正在被用于提高早期检测的效果。在未来,分子生物标志物可能会补充低剂量计算机断层扫描,并提高早期肺癌检测的稳健性。